Current research indicates that SGLT-2 inhibitors, such as empagliflozin and dapagliflozin, have potential neuroprotective effects that could reduce the risk of dementia and improve cognitive function in patients with type 2 diabetes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.